By Elena Vardon

Shares in ImmuPharma PLC rose 24% on Monday after the group and its partner Avion Pharmaceuticals confirmed that a Phase 2/3 adaptive trial will be the best design for its Lupuzor lupus treatment's next clinical study.

At 0823 GMT, shares were up 0.63 pence at 3.25 pence.

The pharmaceutical company said the study is expected to start in the second half of 2023 after submission through the Food and Drug Administration and Prescription Drug User Fee Act process.

It said the study is expected to be cheaper and the overall timelines faster as the need to stop and start two independent trials, regulatory checks, ethics approvals and site setups are avoided.

Write to Elena Vardon at elena.vardon@wsj.com

(END) Dow Jones Newswires

February 06, 2023 03:43 ET (08:43 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Immupharma Charts.